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OBJECTIVES: The Losartan Intervention For Endpoint Reduc-
tion (LIFE) in hypertension study was a randomised, double-
blinded trial comparing effects of losartan with atenolol on
cardiovascular morbidity and death. A population of 9193
hypertensive patients with left ventricular hypertrophy (LVH) in
different countries was studied. As compared to atenolol, losar-
tan reduced the combined risk of cardiovascular morbidity and
mortality by 13% (p = 0.021), and reduced risk of stroke by
25% (p = 0.001), despite comparable blood pressure control.
Our objective was to conduct a cost-effectiveness analysis of
losartan compared with atenolol from the Dutch health care per-
spective. METHODS: Utilisation of losartan and atenolol within
the trial period and an estimation of direct medical costs of
stroke for The Netherlands were combined with estimates of
reduction in life expectancy through stroke. Medication cost and
stroke incidence during 5.5 years of patient follow-up were esti-
mated separately, adjusted for the baseline degree of LVH and
Framingham risk score. To estimate lifetime stroke costs, the
cumulative incidence of stroke was multiplied by the lifetime
direct medical costs attributable to stroke. All costs in 2004
Dutch prices were discounted at 4%, and effects at 1.5% (new
guideline). RESULTS: Prevention of stroke resulted in a gain of
5.1 discounted life years. As a consequence, losartan treatment
resulted in 0.081 life years gained per patient. Losartan reduced
stroke related cost by €946. After inclusion of study medication
cost, net cost per patient was €237 higher for losartan than
atenolol. The net cost per life year gained was €2926 which is
below the Dutch pharmacoeconomic threshold of €20,000/LYG
for accepting interventions. The corresponding probability of a
cost-effectiveness ratio below the Dutch threshold was 0.96.
CONCLUSIONS: In The Netherlands, treatment with losartan
compared with atenolol is a cost-effective intervention based on
the reduced risk of stroke observed in the LIFE trial.
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OBJECTIVES: To assess the costs effectiveness of 18-month
treatment with clopidogrel followed by aspirin versus aspirin
long life in high-risk patients with recent ischemic stroke (IS) or
transient ischemic attack (TIA) in Italy. METHODS: A Markov
model was developed to perform an indirect comparison. This
model was run with a lifetime perspective, for a cohort aged 66
(63% male). During their lifetime, patients can experience quar-
terly following events: IS, myocardial infarctions (MI), TIA,
other cardiovascular deaths, primary intracranial hemorrhages,
life threatening bleedings, or major bleedings. For the clopido-
grel arm, the events rates were taken from the recent MATCH
trial. In order to derive the aspirin arm, we applied a relative risk
increase (RRI) of 1.11 taken from the Cochrane review for car-
diovascular events, and a RRI of 1.12 from the CAPRIE trial for
hemorrhagic events. Costs were retrieved using Italian Diagno-
sis Related Group (DRG) and published sources. Annual dis-
count rate of 3% was applied for both costs and beneﬁts. Payer
perspective was used. Extensive sensitivity analyses were per-
formed. RESULTS: For a cohort of 10,000 patients, 18-month
treatment with clopidogrel instead of aspirin allow to avoid 138
recurrent IS, 28 MI, and 27 cardiovascular deaths. Clopidogrel
treatment is associated with a gain in quality adjusted life years
(QALY) of 360 years. Incremental total cost per patient (includ-
ing drugs and complications), over a remaining lifetime horizon
was €702. Incremental cost-effectiveness ratio (ICER) was
€19,500 / QALY with 57% of simulations below the acceptable
€23,000 / QALY threshold. CONCLUSIONS: In patients at high
risk of ischemic events with recent TIA or IS, 18-month treat-
ment with clopidogrel followed by continuation on aspirin was
projected to improve life expectancy, reduce risk of secondary
ischemic events and be cost-effective compared to aspirin over
patient lifetimes in Italy.
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OBJECTIVES: To compare the total costs of the Handmaster
treatment as addition to the current standard treatment of post
stroke patients with the costs of the current standard treatment
alone. METHODS: A health economic model was used to
perform a cost-consequence analysis in order to determine cost
savings resulting from the clinical effects of the Handmaster. The
patient population consisted of severe patients with a score of 4
or 5 according to the Modiﬁed Ashworth Scale and with a non-
functional upper extremity. The data sources were published lit-
erature, including the Handmaster clinical trials, Delphi panel
and ofﬁcial price/tariff lists. The primary perspective of the study
was that of the health insurer in The Netherlands. RESULTS:
The costs of treatment with the Handmaster consist of purchas-
ing and service costs. Linear depreciation was applied to the pur-
chase costs. The use of the Handmaster resulted in net cost
savings of €320 and €477, respectively at the end of year 1 and
over the 5-year period. Sensitivity analysis showed that outcomes
for the model were most sensitive to frequency and intensity of
physiotherapy. CONCLUSION: Although treatment with the
Handmaster requires an initial investment, purchase and service
costs are largely compensated by saving of costs in other com-
ponents of the regular medical care in the chronic phase post
stroke.
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OBJECTIVE: To assess the economic and epidemiologic impact
of stoke in Friuli Venezia Giulia (FVG) a region of approximately
1.2 million inhabitants in the north-eastern Italy. METHODS:
All residents of FVG are registered in to Regional Health Service
(RHS) database, which keeps tracks of the use of medical care
admissions and reimbursement purposes. We selected residents
of FVG who had during year 2000 a ﬁrst stoke hospital admis-
sion and we followed them up till death, or December 31, 2004.
(we a priory excluded people who during the period 1995–1999
had a previous CVD event). Mortality was investigated by col-
lecting information from Regional Citizen Register ﬁle. We
obtained information on medical costs from electronic databases
of prescriptions, hospitalizations, visits and diagnostic examina-
tions in FVG. Direct medical costs were quantiﬁed in the per-
spective of the RHS and are expressed in Euro 2005. RESULTS:
We enrolled 936 patients with incident stroke (mean age 77 ±
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12y.o.), 55.4% were women. The average cost person/year was
euro 3502.87; 73.9% attributable to hospitalisations, 17.5% to
drugs, 8,6% to other medical costs. The 32.8% patients died
during the follow up period, with a mean age of 84 ± 9 statisti-
cally different (p < 0.0001) from survivors (mean age 74 ± 11
y.o.). CONCLUSIONS: Stroke imposes a large social and eco-
nomic burden on NHS and society because of the large number
of hospitalisation and the high rate of mortality. Future investi-
gations will be conduct to asses the relationships between comor-
bidity, costs, drug therapy and survival.
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OBJECTIVES: To assess factors inﬂuencing acute hospitalization
for patients with ﬁrst-ever ischemic stroke in Taiwan.
METHODS: Data were prospectively collected from 360 ﬁrst-
ever ischemic stroke patients consecutively admitted to a medical
center within 48 hours after symptom onset. Longer stay was
deﬁned as length of stay (LOS) >7 days after admission in depart-
ment of neurology for acute care. The association between demo-
graphic characteristics or clinical variables and LOS was
examined using multivariate logistic regression analysis. Dis-
crimination of the model was assessed by the area under the
receiver operating characteristic curve, and calibration was
assessed using goodness of ﬁt test. RESULTS: Patients (58%
male) had mean age 64.9 ± 12.7 (range, 18 to 93) years. Median
National Institutes of Health Stroke Scale (NIHSS) score at
admission was 6 (25th to 75th percentile, 3 to 12), median mod-
iﬁed Barthel Index (MBI; on a scale of 0 to 20) at admission was
12 (25th to 75th percentile, 5 to 16). The LOS was >7 days in
169 (47%) patients. Male sex (odds ratio [OR], 1.7; 95% CI,
1.0 to 2.8), baseline NIHSS score 7–15 (versus 0–6) (OR, 2.9;
95% CI, 1.5 to 5.7), baseline NIHSS score ≥16 (versus 0–6) (OR,
3.1; 95% CI, 1.3 to 7.4), baseline MBI ≥12 (OR, 0.5; 95% CI,
0.3 to 1.0), and small vessel occlusive subtype (OR, 0.35; 95%
CI, 0.2 to 0.6) were independent predictors of longer stay. Good-
ness-of-ﬁt test (Hosmer-Lemeshow test) was not signiﬁcant (P =
0.49), indicating adequate ﬁtness. The model’s discrimination
was adequate with an under the curve area (receiver operating
characteristic curve) of 0.776. CONCLUSIONS: The impact of
stroke severity need to be understood to manager LOS. Early
supported discharge planning would probably reduce the LOS
in acute hospitalization of this group of ﬁrst-ever ischemic stroke
patients.
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OBJECTIVES: Clinical practice guidelines and several clinical
trials support the use of warfarin for stroke prevention in most
patients with atrial ﬁbrillation (AF). Warfarin should not be used
in cases where contraindications exist or the risk of stroke is low.
It is not clear what proportion of are there patients at risk of
stroke and without contraindications do not receive warfarin in
practice. METHODS: A MEDLINE search was conducted
(1966–2001) using the MeSH terms anticoagulants, AF, warfarin
and cerebrovascular disorder (prevention and control). Practice-
based studies reporting the proportion of patients eligible to
receive warfarin (i.e., no contraindications to thromboprophy-
laxis and at moderate or high risk of stroke) who actually
received warfarin for stroke prevention in AF were retrieved.
RESULTS: Twenty-one practice-based studies were found, of
which 3 were excluded because the patient population or
centre/setting signiﬁcantly varied from the other identiﬁed
studies. Approximately 47–89% of patients enrolled in the
remaining 18 studies were eligible for stroke prevention. Only
15–64% of eligible patients received warfarin and 15–56% did
not receive any form of stroke prevention therapy at all (i.e., no
warfarin or antiplatelet agent). CONCLUSIONS: Despite the
publication of multiple clinical trials and practice guidelines sup-
porting the use of warfarin for stroke prevention in AF, many
eligible patients do not receive appropriate preventive therapy,
and therefore remain at increased risk of stroke. Reasons for the
sub-optimal use of warfarin for stroke prevention in AF require
further research.
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WARFARIN PATIENT SEGMENTS: GENERAL PRACTITIONERS
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OBJECTIVES: There is a documented lack of treatment and
undertreatment with warfarin in AF patients. GPs and Special-
ists (SPs) may take different approaches to anticoagulation for
their AF patients. The objective is to identify, compare and 
quantify warfarin patient segments for both SPs and GPs.
METHODS: Physicians from Toronto, Montreal and Vancouver,
randomly recruited from lists of high warfarin prescribers, par-
ticipated in 60 minute qualitative interviews. Thirty-Six physi-
cians were interviewed (14GPs, 8 Cardiologists, 6 Internists and
3 Haematologists). RESULTS: SPs placed patients in 3 major 
segments: untreated (5% of their patients), treated (90–95%)
and undertreated (5%). GPs had only 2 segments: untreated
(10–25%) and treated (75–90%). Both physician groups identi-
ﬁed untreated patients as those at risk of falling, demented, prone
to bleed, immobile or refusing treatment. SPs referred to under-
treated patients as those using ASA. GPs saw ASA users as part
of their treated group. The other segment within the GP treated
group was warfarin users. SPs divided their treated segment into
well-controlled and not well-controlled. CONCLUSION: SPs
and GPs use similar criteria in determining which patients do not
receive warfarin. However, views on the value of ASA seem dif-
ferent. Further, GPs in this study did not distinguish between well
and not-well controlled warfarin, but rather indicated ASA vs.
warfarin users are both considered treated. Further research is
required to further investigate the differences in opinion, lack of
treatment and to quantify each segment.
PST9
MANDARIN VERSION OF STROKE IMPACT SCALE:
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OBJECTIVES: To assess the properties of the Mandarin version
of the Stoke Impact Scale (SIS) versions 3.0, developed by Pamela
W. Duncan et al. METHODS: The SIS, a stroke-speciﬁc outcome
measure, assesses 8 domains: strength (4 items), memory (7
items), emotion (9 items), communication (7 items), activities of
daily living/instrumental activities of daily living (ADL/IADL)
(10 items), mobility (9 items), hand function (5 items), and par-
ticipation (8 items). SIS was translated and back-translated
